Skip Navigation LinksHome > Published Ahead-of-Print > Therapy-induced Secondary Acute Myeloid Leukemia With t(11;1...
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0000000000000183
Clinical and Laboratory Observations: PDF Only

Therapy-induced Secondary Acute Myeloid Leukemia With t(11;19)(q23;p13.1) in a Pediatric Patient With Relapsed Acute Promyelocytic Leukemia.

Dang, Daniel N. MD; Morris, Heather D. DO; Feusner, James H. MD; Koduru, Prasad PhD; Wilson, Kathleen MD; Timmons, Charles F. MD, PhD; Cavalier, MaryEllen MD; Luu, Hung S. PharmD, MD

Published Ahead-of-Print
Collapse Box

Abstract

Acute myeloid leukemia is classified based upon recurrent cytogenetic abnormalities. The t(15;17)(q24.1;q21.1) abnormality is found in 5% to 8% of de novo acute myeloid leukemia and is diagnostic of acute promyelocytic leukemia (APL). The translocation results in fusion of the retinoic acid receptor-[alpha] (RARA) gene at 17q21.1 and the promyelocytic leukemia (PML) gene at 15q24.1. Standard APL therapy is a combination of all-trans retinoic acid and anthracycline-based chemotherapy. Anthracycline treatment is associated with secondary clonal chromosomal aberrations that can lead to therapy-related secondary myeloid neoplasms. We present a pediatric case of relapsed APL coexistent with treatment-associated secondary myeloid neoplasm with t(11;19)(q23;p13.1).

(C) 2014 by Lippincott Williams & Wilkins.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/JPHOonline

For additional oncology content, visit LWW Oncology Journals on Facebook.